MITF and melanoma: Another study suggests, however, that intrinsically resistant melanomas can be characterized by low expression/activity of MITF accompanied by enhanced activity of NF-κB signaling, and BRAF inhibition in MITF-high, drug-sensitive cells induces a transition to the MITF-low/NF-κB–high state [114].